Thandiwe Gray, MD
Hematology & Oncology · Bismarck, NDNPI 1194884338
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations.
Across 131 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$211
- Johnson & Johnson$200
- Exelixis Inc.$152
- Novartis$136
- Sobi, Inc$100
- GSK$99
- plus $1K from 43 others
Across 1 payment — averaging $101,273 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$101K
What the payments were for
- Food & beverage$2,14791%
- Education$2149%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,361 in reported general payments places this provider in the 75th percentile of 35 hematology & oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 12 | $256,887 |
| KisqaliRibociclib Succinate | 18 | $252,600 |
| RevlimidLenalidomide | 15 | $248,172 |
| BrukinsaZanubrutinib | 21 | $240,958 |
| XtandiEnzalutamide | 16 | $220,663 |
| IbrancePalbociclib | 13 | $202,524 |
| ImbruvicaIbrutinib | 13 | $201,182 |
| EliquisApixaban | 31 | $25,925 |
| Imatinib Mesylate | 28 | $24,292 |
| Anastrozole | 449 | $10,499 |
| Letrozole | 138 | $3,689 |
| Raloxifene Hcl | 76 | $2,773 |
| Exemestane | 23 | $2,293 |
| Tamoxifen Citrate | 45 | $1,355 |
| Hydroxyurea | 44 | $932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $42 | $256,88712 claims |
| NovartisKisqali | $136 | $252,60018 claims |
| Bristol Myers SquibbRevlimid | $66 | $248,17215 claims |
| PfizerIbrance, Eliquis | $98 | $228,44944 claims |
| Astellas Pharma US IncXtandi | $23 | $220,66316 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $11 | $12916 claims |
| Lilly USA, LLCOlanzapine | $18 | $8320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 35 hematology & oncology providers in North Dakota.
Other hematology & oncology in Bismarck
- Peter KurnialiBismarck$8K
- Matthew McGeeBismarck$3K
- Stewart SharpBismarck$2K
- Sagar RakshitBismarck$2K
- John ReynoldsBismarck$2K
- Alexander JohnsonBismarck$1K
- Edward WosBismarck$1K
- Aaron LuebkeBismarck$829
- David Oladele-BankoleBismarck$16
- Baruti SerabeBismarck$14
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.